Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab

Neil J. Shah, Sneha Sura, Reshma Shinde, Junxin Shi, Puneet K. Singhal, Rodolfo F. Perini, Robert J. Motzer

2023Urologic Oncology Seminars and Original Investigations15 citationsDOI

Topics & Concepts

IpilimumabPembrolizumabMedicineNivolumabAxitinibInternal medicineRenal cell carcinomaOncologyProportional hazards modelCohortCancerImmunotherapySunitinibRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis

Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab

Topics & Concepts

Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab